CLAIM CARD
The evidence for rapamycin's effects on healthspan and quality of life in humans is represented by a planned clinical trial. The study population will include women with a T-score >-3 and no history of hip, Colles', or symptomatic vertebral fractures within the last 6 months. The primary endpoint is the prevention of bone loss, a key component of musculoskeletal healthspan. The planned intervention involves everolimus, a rapamycin analogue, and/or exercise.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025